<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03963479</url>
  </required_header>
  <id_info>
    <org_study_id>BSMMU/2018/14607</org_study_id>
    <nct_id>NCT03963479</nct_id>
  </id_info>
  <brief_title>Vitamin B6 and Magnesium- A Clinical Trial on ASD Patients</brief_title>
  <official_title>Vitamin B6 and Magnesium on Neurobehavioral Status of Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether Vitamin B6 and Magnesium improve neurobehavioral status in terms of
      General observation, Cognitive working, Socialization, Communication and Sensory Dysfunction
      in patient with Autism Spectrum Disorder.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Autism Spectrum Disorder</measure>
    <time_frame>3 months</time_frame>
    <description>General observation, Cognitive Working, socialization, Communication, Sensory Dysfunction.
At first a autism will be diagnosed by DSM-5 .Then the above mention criterias along with the severity will be diagnosed by Autism Diagnostic Checklist tool by a psychologist.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Autism Spectrum Disorder</measure>
    <time_frame>0 month</time_frame>
    <description>The Autism Diagnostic Checklist will be repeated to compare the outcomes in terms of General observation, Cognitive Working, socialization, Communication, Sensory along with the severity of the Autism.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Magnesium-Vitamin B6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Magnesium (50mg) for ages 1-3 years (100mg) for ages 4-8 years (200mg) for ages 9-12 years Vitamin B6 (25mg) for ages 1-3 years (50mg) for ages 4-8 years (100mg) for ages 9-12years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Magnesium (50mg) for ages 1-3 years (100mg) for ages 4-8 years (200mg) for ages 9-12 years Vitamin B6 (25mg) for ages 1-3 years (50mg) for ages 4-8 years (100mg) for ages 9-12years</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Magnesium and Vitamin B6</intervention_name>
    <description>Magnesium and Vitamin B6 will be given to the enrolled patients for 3 months</description>
    <arm_group_label>Magnesium-Vitamin B6</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children between 2 to 12 years of age suspected ASD assessed by DSM-5 and ADCL tool

          2. Each patient will be free of psychoactive medication for atleast 3 months prior to the
             entry into the trial

          3. Newly diagnosed patient

          4. Co-morbid neurological disorder like hyperactivity

        Exclusion Criteria:

          1. Patients with chronic diseases or any known metabolic or hormonal diseases

          2. Patients with any known chromosomal or genetic syndromes

          3. Patients unable to give informed consent

          4. Patients unable to travel to clinical visits or non co-operative
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Farhana Khan, MBBS</last_name>
    <phone>8801674255083</phone>
    <email>farhanakhan488@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Md Sayedur Rahman, MBBS, MPhil</last_name>
    <phone>8801971840757</phone>
    <email>srkhasru@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Farhana Khan</name>
      <address>
        <city>Dhaka</city>
        <zip>02</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Md. Sayedur Rahman, MBBS, MPhil</last_name>
      <phone>8801971840757</phone>
      <email>srkhasru@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</investigator_affiliation>
    <investigator_full_name>Dr. Farhana Khan</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 6</mesh_term>
    <mesh_term>Pyridoxal</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

